Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
07:30am, Wednesday, 02'nd Jun 2021
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
07:30am, Tuesday, 18'th May 2021
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
07:05am, Monday, 03'rd May 2021
Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees Flavia Borellini, P
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
07:00am, Wednesday, 21'st Apr 2021
First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development
This 2020 Biotech IPO Is Poised to Break Out in 2021
06:15am, Friday, 02'nd Apr 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
04:05pm, Thursday, 11'th Mar 2021
Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RA
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
04:05pm, Tuesday, 02'nd Mar 2021
Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
07:30am, Thursday, 18'th Feb 2021
Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion Steve Kelsey, M.D., President, Research and Development, to Pr
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
11:30pm, Wednesday, 03'rd Feb 2021
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at
Revolution Medicines Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 01'st Feb 2021
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common st
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets
Why Revolution Medicines Stock Is Trading Higher
03:45pm, Thursday, 12'th Nov 2020
Revolution Medicines (NASDAQ: RVMD) shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of $6.08 year-over-year and sales $12.66 milli
